Abstract: Disclosed here is an adenosine derivative prodrug that can have reverse transcriptase inhibitor activity in vivo. This disclosure is also directed to a pharmaceutical composition comprising the adenosine derivative that can be used for the treatment of HIV infection or RNA virus infection.

Abstract: The present invention relates to a composition for surface modification. The composition for surface modification according to the present invention contains a particular carbodiimide-based compound, thus forms a covalent bond without damaging skin, hair, or fabric, and semipermanently provides desired skin or hair surface modification effects or fabric care effects.

Abstract: The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.

Abstract: A method of treating insulin resistance includes administering to a subject a pharmaceutical composition comprising diethyl azelate. For example, a method of treating insulin resistance includes orally administering to a subject a pharmaceutical composition that includes diethyl azelate at a dosage range from about 0.1 mg/kg/day to about 10 mg/kg/day.

Abstract: The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and a DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.

Abstract: The purpose of the present invention is to provide a rivastigmine-containing transdermal absorption preparation having high adhesion to the skin and capable of continuously administering rivastigmine over a long period of time. A transdermal absorption preparation has rivastigmine, a rubber polymer, a tackifier resin, and a polymer compound having a nitrogen-containing group.

Abstract: This invention relates to methods comprising administering a FAK inhibitor (e.g., VS-6063) in combination with a dual RAF/MEK inhibitor (e.g., CHS 126766) that are useful in the treatment of abnormal cell growth, such as cancer, in a subject such as humans.

Abstract: A method of delivering insulin, including: orally administering to a subject a composition containing a ferrisilicate material, polyethylene glycol, and insulin. The insulin at least partially penetrates pores of the ferrisilicate material to form a ferrisilicate insulin composite and the polyethylene glycol, at least partially enfolds the ferrisilicate insulin composite to form the composition. The composition has an insulin release rate of 10-50% after 100-500 hours following oral administration.

Abstract: The present invention relates to stable injectable compositions comprising meloxicam or its pharmaceutically acceptable salts, solvates, or hydrates thereof, wherein the composition is provided in a sealed container, e.g., an ampoule, vial and pre-filled syringe. Further, the present invention relates to a stable injectable solution comprising meloxicam or its pharmaceutically acceptable salts, solvates, or hydrates thereof, suitable for subcutaneous, intravenous or intramuscular administration. The invention relates to methods for manufacturing stable injectable solutions of meloxicam. The present invention further relates to a method of treating pain by parenterally administering to a patient in need thereof a composition comprising a stable solution of meloxicam, wherein said solution provides rapid onset of action for pain relief compared to a reference composition.

Abstract: Provided is a sustained-release lipid pre-concentrate in the form of a lipid solution, including an unsaturated fatty acid having 14 to 20 carbon atoms (C14˜C20); a phospholipid; and ?-tocopherol acetate, wherein the sustained-release lipid pre-concentrate is free of diacyl glycerol and sorbitan unsaturated fatty acid ester; and forms a liquid crystal in an aqueous medium. Further provided is a sustained-release injectable pharmaceutical composition in the form of a lipid solution, including the pre-concentrate and a pharmacologically active substance, wherein the sustained-release injectable pharmaceutical composition is free of diacyl glycerol and sorbitan unsaturated fatty acid ester.

Abstract: Stable crystal forms comprising lithium ions and the conjugate base of an organic acid which is in the form of anhydrous coordination polymer that exhibit improved in vivo performance with respect to lithium carbonate.

Abstract: Suggested is a composition with stabilized taste and/or odor, comprising (a) [6]-paradol and (b) at least one mono- or polyunsaturated C8-C22 fatty acid or its monohydric or polyhydric C1-C18 aliphatic alcohols ester.

Abstract: Described are pharmaceutical compositions in fixed dose combinations containing: a) a dofetilide component; and b) a mexiletine component; wherein the dofetilide component and the mexiletine component are physically separated from each other, along with methods of treating or preventing atrial fibrillation or a symptom associated therewith in a subject in need thereof by administering to the subject such a pharmaceutical composition and methods of preparing such fixed dose combination products.

Abstract: Provided is an agricultural or horticultural fungicide that has low toxicity to humans and animals, that is excellent in handling safety, and that has an excellent controlling effect against a wide range of plant diseases and a high antimicrobial action against plant disease fungi. The agricultural or horticultural fungicide of the present invention includes, as an active ingredient, an azole derivative represented by the following general formula (I) and other active ingredients.

Abstract: The present invention relates to a liquid pharmaceutical formulation, which is stable at room temperature, being essentially free of water, comprising a) at least one easily degradable active pharmaceutical ingredient, b) at least one pharmaceutically acceptable organic solvent and c) at least one pharmaceutically acceptable alkaline earth metal salt and its use in medicine.

Abstract: Compositions contain an amount of cinnamaldehyde that is orally tolerable, thus avoiding an unpleasant mouth feeling, and also tolerable in the gastrointestinal tract. The amount of cinnamaldehyde is supplemented by zinc, and the combination is effective to promote a swallowing reflex. The composition containing the combination of cinnamaldehyde and zinc can be used in a method to treat dysphagia and/or prevent aspiration pneumonia from dysphagia. In an embodiment, the composition containing cinnamaldehyde is administered to a human. The composition containing cinnamaldehyde may be a medicament, a food product or a supplement to a food product.

Abstract: Disclosed is a topical composition comprising: (i) an antimicrobial active which is at least one of piroctone, caprylhydroxamic acid, benzohydroxamic acid, or piroctone olamine; and (ii) Febrifugine. Also disclosed is a non-therapeutic method of providing topical antimicrobial benefit on a topical surface of a human or animal body comprising a step of applying a safe and effective amount of the topical composition.

Abstract: A composition comprising stabilised organo-silanol compounds, said composition comprising two different organo-silanols and an organo-silanol(s) stabilising/complexing agent.

Abstract: Hand sanitizers are provided with improved aesthetics and skin-conditioning effects, such that healthcare workers and others subject to high frequency hand hygiene requirements are encouraged to comply with said requirements. The hand sanitizers provide excellent antimicrobial efficacy and skin conditioning benefits that actually increase with increased frequency of use. The sanitizing compositions are hydroalcoholic, and contain a synergistic combination of skin-conditioning agents.

Abstract: The present disclosure relates to pharmaceutical solid forms and pharmaceutical compositions comprising ibutamoren or a pharmaceutically acceptable salt thereof, and methods for administering to a pediatric subject for treating growth hormone deficiency.